mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma

Medicine and Dentistry

• In Vitro 100%
• Head and Neck Squamous Cell Carcinoma 100%
• Mammalian Target of Rapamycin 100%
• Bladder Cancer 100%
• Temsirolimus 50%
• Neoplasm 33%
• Percutaneous Coronary Intervention 33%
• Programmed Cell Death 33%
• Protein Expression 33%
• Small Interfering RNA 33%
• Head and Neck Squamous Cell Carcinoma Cell Line 16%
• Flow Cytometry 16%
• Western Blot 16%
• Target Protein 16%
• Bladder Carcinoma Cell Line 16%
• Cell Line 16%
• Genetic Transfection 16%
• Cell Cycle Checkpoint 16%
• Cell-Cycle Analysis 16%
• Cell Cycle Arrest 16%
• MTT Assay 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Bladder Cancer 100%
• Mammalian Target of Rapamycin Inhibitor 100%
• Head and Neck Squamous Cell Carcinoma 100%
• Temsirolimus 75%
• Small Interfering RNA 50%
• Neoplasm 50%
• Cell Viability 25%
• Flow Cytometry 25%
• Western Blot 25%
• Bladder Carcinoma 25%